Boule Diagnostics publishes Annual Report for 2011, and audit report with remark
In light of the shortcomings that existed during 2011 in the parent company regarding fees and charges, Boule notes that the delays are not due to lack of liquidity but due to temporary shortcomings in the administrative procedures. The latter has been corrected so that the problem will not be repeated. The delays in payment have only incurred negligible costs for the company.
For more information, please contact:
Ernst Westman, President CEO of Boule Diagnostics AB
Phone: 0708-60 88 63, e-mail: ernst.westman@boule.se
TILL REDAKTÖRERNA
Om Boule Diagnostics AB
Boule Diagnostics AB is a fast-growing diagnostics company, developing and manufacturing systems and consumables for hematology diagnostics for the public healthcare providers worldwide. The company is primarily focused on small and medium-sized hospitals, clinics and laboratories in outpatient care as well as other diagnostics companies in both human and veterinary haematology. The group is comprised of operating subsidiaries in Sweden, the US and China. Boule Diagnostics’ share is, since 2011, traded on NASDAQ OMX Nordic. www.boule.se
Latest news
-
Boule Diagnostics – Invitation to presentation of the interim report Q1 2025 23 Apr, 2025
-
Boule Diagnostics – Inbjudan till presentation av Q1 2025 23 Apr, 2025
-
Boule Diagnostics publicerar årsredovisningen för 2024 11 Apr, 2025
-
KALLELSE TILL ÅRSSTÄMMA I BOULE DIAGNOSTICS AB 7 Apr, 2025
-
Boule Diagnostics meddelar stängning av BM950-projektet och ny portföljstrategi 12 Mar, 2025
-
Valberedningens förslag till styrelse 2025 26 Feb, 2025
-
Boule Diagnostics bokslutskommuniké 2024 11 Feb, 2025
-
Boule Diagnostics AB: Boule Diagnostics ingår distributionsavtal med VitalScientific 7 Feb, 2025